Updated Story Patients for Biologics Safety & Access is calling on FDA to rework portions of its newly released web page meant to educate prescribers about biosimilars, with the group suggesting changes aimed at downplaying the agency's safety assurances. The group -- which has continually sounded the alarm over potential risks of biosimilars, despite admission from the group's head that the group doesn't have concrete evidence of higher adverse events with the drugs -- wants FDA to...